▁Eli ▁L illy ; ▁T arg anta ▁acquired ▁world wide ▁rights ▁to ▁or it av anc in ▁from ▁Inter M une ▁in ▁late ▁ 2 0 0 5 . ▁Data ▁presented ▁at ▁the ▁ 4 7 th ▁Ann ual ▁In ters cience ▁Conference ▁on ▁Ant im icro b ial ▁Ag ents ▁and ▁Chem other apy ▁( IC A AC ) ▁in ▁September ▁ 2 0 0 7 ▁demonstrated ▁that ▁or it av anc in ▁poss esses ▁pot ent ▁and ▁rapid ▁b acter ic idal ▁activity ▁in ▁vit ro ▁against ▁a ▁broad ▁spectrum ▁of ▁both ▁resist ant ▁and ▁sus cept ible ▁Gram - pos itive ▁b acter ia , ▁including ▁St ap hy loc oc cus ▁a ure us , ▁m eth ic ill in - res istant ▁St ap hy loc oc cus ▁a ure us , ▁Enter oc oc ci , ▁Clo str id ium ▁diff icile ▁and ▁Stre pt oc oc ci . ▁Results ▁have ▁been ▁presented ▁but ▁not ▁yet ▁published ▁from ▁two ▁p iv otal ▁Ph ase ▁ 3 ▁clin ical ▁tri als ▁testing ▁the ▁effic acy ▁of ▁or it av anc in ▁for ▁the ▁treatment ▁of ▁Comp licated ▁skin ▁and ▁skin - structure ▁in fe ctions ▁( c SS SI ) ▁caused ▁by ▁Gram - pos itive ▁b acter ia . ▁The ▁primary ▁end points ▁of ▁both ▁studies ▁were ▁successfully ▁met , ▁with ▁or it av anc in ▁ach ieving ▁effic acy ▁with ▁fewer ▁days ▁of ▁ther apy ▁than ▁the ▁compar ator ▁agents ▁( van com yc in ▁followed